|
| |
| |
-
Oettel M., Buvat J.,
Eardley I., Heufelder A., Plas E., Behre H.M.:
“New
Developments in Testosterone Therapy – a Congress Report“
J.Reproduktionsmed.Endokrinol., 5, 2, (70-75), 2008
-
Daha L., Lazar D.,
Simak R., Pflüger H.:
“The effects
of intravesical pentosanpolysulfate treatment on the symptoms of
patients with bladder pain syndrome / interstitial cystitis:
preliminary results“
Int.Urogynaecol.J., 19, (987-990), 2008
The objective of the study was to determine
whether intravesical pentosanpolysulfate (PPS) reduces symptoms
associated with bladder pain syndrome/interstitial cystitis
(BPS/IC). In a prospective, uncontrolled, open-label study, 29
female patients with BPS/IC received 300 mg PPS intravesically twice
a week for 10 weeks and thereafter a voluntary maintenance therapy
once a month. Treatment response was assessed by Visual Analog Scale
(VAS) for quality of life and O'Leary-Sant Symptom and Problem Index
(OSPI). Patients were tested before treatment, after 5 weeks of
treatment, and 1 week, 3, 6, and 12 months after termination of the
initial treatment. Twenty-five patients underwent the 10-week
treatment and the 3-month follow-up. Mean reduction of VAS/OSPI was
from 8.8/26.4 before to 4/15.3 after treatment, 3.8/15.2 after 3
months, 3.8/14 after 6 months, and 3.4/12.1 after 12 months. In 21
patients, renewed instillation or maintenance therapy was necessary.
Intravesical treatment with PPS reduces both the VAS and the OSPI in
patients with BPS/IC.
-
Riedl C.R.,
Engelhardt P., Daha L., Morakis N., Pflüger H.:
“Hyaluron
treatment of interstitial cystitis / painful bladder syndrome“
Int.Urogynaecol.J., 19, 5, (717-721), 2008
-
Stancik I., Plas E.,
Juza J., Pflüger H.:
“Effect of
Antibiotic Therapy on Interleucin-6 in Fresh Semen and
Postmasturbation Urine Samples of Patients with Chronic Prostatitis
/ Chronic Pelvic Pain Syndrome“
Urology,
72, 2, (336-339), 2008
-
Van de Merwe JP,
Nordling J., Bouchelouche P., Boucheloche K., Cervigni M., Daha L.,
Elneil S., Fall M., Hohlbrugger G., Irwin P., Mortensen S., van
Ophoven A., Osborne J.L., Peeker R., Richter B., Riedl C., Sairanen
J., Tinzl M., Wyndaele J.J.:
“Diagnostic
criteria, classification and nomenclature for painful bladder
syndrome / interstitial cystitis: an ESSIC proposal“
Eur.Urol,
53, 1, (60-7), 2008
OBJECTIVES: Because the term "interstitial cystitis"
(IC) has different meanings in different centers and different parts
of the world, the European Society for the Study of Interstitial
Cystitis (ESSIC) has worked to create a consensus on definitions,
diagnosis, and classification in an attempt to overcome the lack of
international agreement on various aspects of IC. METHODS: ESSIC has
discussed definitions, diagnostic criteria, and disease
classification in four meetings and extended e-mail correspondence.
RESULTS: It was agreed to name the disease bladder pain syndrome
(BPS). BPS would be diagnosed on the basis of chronic pelvic pain,
pressure, or discomfort perceived to be related to the urinary
bladder accompanied by at least one other urinary symptom such as
persistent urge to void or urinary frequency. Confusable diseases as
the cause of the symptoms must be excluded. Classification of BPS
types might be performed according to findings at cystoscopy with
hydrodistention and morphologic findings in bladder biopsies. The
presence of other organ symptoms as well as cognitive, behavioral,
emotional, and sexual symptoms, should be addressed. CONCLUSIONS:
The name IC has become misleading and is replaced by BPS. This name
is in line with recent nomenclature recommendations by the European
Association of Urology and is based on the axial structure of the
International Association for the Study of Pain classification. To
facilitate the change of the name, ESSIC agreed to include IC in the
overall term (BPS/IC) during this transition period.
-
Daha L., Riedl C.,
Lazar D., Simak R., Pflüger H.:
“Effect of
intravesical glycosaminoglycan substitution therapy on bladder pain
syndrome / interstitial cystitis, bladder capacity and potassium
sensitivity“
Scand.J.Urol.Nephrol., 42, 4, (369-372), 2008
OBJECTIVE: To evaluate changes in bladder capacity
and potassium sensitivity after glycosaminoglycan (GAG) substitution
therapy. MATERIAL AND METHODS: The study population comprised two
groups of female patients with bladder pain syndrome/interstitial
cystitis (BPS/IC): responders (those with symptom improvement) and
non-responders (those without symptom improvement) after a 10-week
period of intravesical, episodic, weekly, GAG substitution therapy.
A total of 27 volunteers with increased pre-therapeutic potassium
sensitivity were enrolled in the study and re-evaluated using the
modified comparative potassium test (maximal bladder capacity with a
saline solution versus a 0.2 M KCl solution) following intravesical
GAG substitution therapy. RESULTS: In the 13 responders, the average
maximal bladder capacity increased by 17% with the saline solution
and by 101.5% with the 0.2 M KCl solution. In the 14 non-responders,
post-therapeutic average maximal bladder capacity was decreased by
35% with the saline solution and remained relatively unchanged after
instillation with a 0.2 M KCl solution. CONCLUSION: These data
demonstrate that in patients who respond symptomatically to
intravesical GAG substitution therapy, cystometric bladder capacity
is increased, whereas non-responders experience a decrease in
bladder capacity.
-
Stancik I., Höltl
W., De Santis M.:
“Peniskarzinom:
Leitlinien des Arbeitskreises für Urologische Onkologie AUO der
Österreichischen Gesellschaft für Urologie und Andrologie“
J.Urol.Urogynäkol., 15, 4, (14-17), 2008
PDF-Vollversion
-
Untergasser G.,
Sampson N., Heinrich E., Rumpold H., Plas E., Berger P.:
“Interferon
gamma induces neuroendocrine-like differentiation of basal
epithelial cells: implications for prostate carcinogenesis“
Abstract, 9th
Int.Symp. on Neurobiology and Neuroendocrinology of Aging,
20.-25.7., 2008
-
Pernkopf D., Pflüger
H.:
“Der
Penis und die Faschingströte oder der lange Weg zur
Pudendaangiographie“
Facharzt,
1, (27-28), 2008
PDF-Vollversion
-
Stancik I.:
“Erste
Erfahrungen mit HIFU als alternative Behandlung“
Urologik,
1, (36-38), 2008
-
Plas E.:
“Erektile
Funktion und Beziehungsqualität“
Universum
Mann, 1, (8-9), 2008
-
Plas E.:
“Erektile
Funktion und Beziehungsqualität“
Ärztekrone,
23, (26-28), 2008
|
|
